-
Proactive
ImmuPharma CEO confident on P140 partnership as strong pharma interest extends timeline into 2026 28 November 2025 ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy talked with Proactive’s Stephen Gunnion about the company’s ongoing discussions to secure a partnership for its lead asset, P140 – November 2025
-
Sunday Roast
Midweek Takeaway featuring Tim McCarthy, CEO of ImmuPharma 26 November 2025 In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. – November 2025
-
Corporate Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions. In the Corporate Update notification of 23 October 2025, ImmuPharma advised that it had started to engage with a number of potential partners on P140, and that the Company’s stated objective was to complete a deal by the…
-
TR1 from Lanstead – Major interest in shares
TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
-
IMMUPHARMA ATTENDING BIO-EUROPE
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025. BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science…
-
Launch of New Website & Corporate Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company’s scientific and corporate evolution and placing its proprietary P140 autoimmune platform at the forefront of its strategy. Website Showcase | P140 Platform – Scientific Advancement and Mechanism of…
-
Charles Archer
Immupharma. The Immunormalizer: How a Small British Biotech Might Have Cracked the Autoimmune Code.
-
Appointment of Independent Non-Executive Director
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect. Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term…
-
All Interviews
Proactive – ImmuPharma “looking forward” to upcoming FDA meetings 27 April 2023 Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023 Ultimate Breakouts with Alan Green discussing Immupharma Plc CEO, Tim McCarthy joins Stockhouse – “Putting Patients…
-
TR1 from Lanstead – Major interest in shares
TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
